Wang N.-N.,Tianjin Hospital of Tianjin |
Tan X.-F.,Tianjin Hospital of Tianjin |
Shen H.,Zhejiang University
Journal of Practical Oncology | Year: 2013
One non-small-cell lung cancer (NSCLO) patient complicated with erlotinib-induced interstitial lung disease (ILD) was reported and 24 more cases were collected from literature search. In 24 cases, ILD occurred from 5 d to 1 y after administration of erlotinib, and in 75. 0% cases (18/24) ILD occurred 5 - 39 d. Risk factors of ILD included older age, male, smoking history, underlying lung disease, history of radiotherapy and chemo herapy. Eleven patients died of respiratory failure and the case fatality rate for patients with high risk factors was higher than 50%.